Crizotinib is a multi-target tyrosine kinase inhibitor that has demonstrated breakthrough efficacy in the treatment of tumors with specific gene mutations. As an oral targeted drug, its precise indication scope, diverse dosage forms and specifications, and standardized storage requirements are of great significance for ensuring treatment safety.

What Are the Indications of Crizotinib?

Metastatic Non-Small Cell Lung Cancer (NSCLC)

It is used for the treatment of adult patients with metastatic non-small cell lung cancer who are confirmed to be anaplastic lymphoma kinase (ALK)-positive or ROS1-positive through FDA-approved detection methods.

Systemic Anaplastic Large Cell Lymphoma (ALCL)

It is indicated for relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma in children aged 1 year and above and young adults.

Special note: The safety and efficacy of crizotinib have not been established in elderly patients with relapsed or refractory systemic ALK-positive ALCL.

Inflammatory Myofibroblastic Tumors (IMTs)

It can be used for the treatment of unresectable, relapsed, or refractory ALK-positive inflammatory myofibroblastic tumors in children aged 1 year and above and adults.

Specifications and Characteristics of Crizotinib

Capsule Dosage Form

200mg: Hard gelatin capsules, size 1, with opaque white bodies and opaque pink caps. The caps are printed with "Pfizer" and the bodies with "CRZ200".

250mg: Hard gelatin capsules, size 0, with opaque pink caps and bodies. The caps are printed with "Pfizer" and the bodies with "CRZ250".

Oral Granule Dosage Form

20mg: Hard gelatin capsules, size 4, with opaque white bodies and opaque light blue caps. Printed with black ink, the caps are marked with "Pfizer" and the bodies with "CRZ20".

Storage Methods for Crizotinib

Uniform Storage Conditions

All dosage forms should be stored at 20°C to 25°C (68°F to 77°F), with allowable fluctuations within the range of 15°C to 30°C (59°F to 86°F).

The shelf life of all specifications of the drug is 3 years.

Special Operation Guidelines

The granules must be removed from the capsule shells before administration.

Swallowing the capsule shells containing granules directly is prohibited.

Drink water immediately after taking the drug to ensure complete swallowing.